Glimepiride: evidence-based facts, trends, and observations (GIFTS). [corrected].

Article Details

Citation
Copy to clipboard

Basit A, Riaz M, Fawwad A

Glimepiride: evidence-based facts, trends, and observations (GIFTS). [corrected].

Vasc Health Risk Manag. 2012;8:463-72. doi: 10.2147/HIV.S33194. Epub 2012 Aug 15.

PubMed ID
23028231 [ View in PubMed
]
Abstract

Type 2 diabetes mellitus is characterized by insulin resistance and progressive beta cell failure; therefore, beta cell secretagogues are useful for achieving sufficient glycemic control. Glimepiride is a second-generation sulfonylurea that stimulates pancreatic beta cells to release insulin. Additionally, is has been shown to work via several extra pancreatic mechanisms. It is administered as monotherapy in patients with type 2 diabetes mellitus in whom glycemic control is not achieved by dietary and lifestyle modifications. It can also be combined with other antihyperglycemic agents, including metformin and insulin, in patients who are not adequately controlled by sulfonylureas alone. The effective dosage range is 1 to 8 mg/day; however, there is no significant difference between 4 and 8 mg/day, but it should be used with caution in the elderly and in patients with renal or hepatic disease. In clinical studies, glimepiride was generally associated with lower risk of hypoglycemia and less weight gain compared to other sulfonylureas. Glimepiride use may be safer in patients with cardiovascular disease because of its lack of detrimental effects on ischemic preconditioning. It is effective in reducing fasting plasma glucose, post-prandial glucose, and glycosylated hemoglobin levels and is a useful, cost-effective treatment option for managing type 2 diabetes mellitus.

DrugBank Data that Cites this Article

Drugs